| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 16241946 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 597 journal articles in the PubMed database | Email to a friend | | |
| Turpie AG, Fisher WD, Bauer KA, et al.
BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. [Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial]
J Thromb Haemost 2005 Nov; 3(11):2479-86.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Eriksson BI, Borris L, Dahl OE, et al.
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. [Journal Article, Multicenter Study, Randomized Controlled Trial]
J Thromb Haemost 2006 Jan; 4(1):121-8.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Fisher WD, Eriksson BI, Bauer KA, et al.
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies. [Journal Article]
Thromb Haemost 2007 Jun; 97(6):931-7.
Abstract | Full Citation | Find Related Articles | | Eriksson BI, Borris LC, Dahl OE, et al.
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. [Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't]
Circulation 2006 Nov 28; 114(22):2374-81.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Fitzgerald RH, Spiro TE, Trowbridge AA, et al.
Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
J Bone Joint Surg Am 2001 Jun; 83-A(6):900-6.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Agnelli G, Haas S, Ginsberg JS, et al.
A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. [Journal Article]
J Thromb Haemost 2007 Apr; 5(4):746-53.
Abstract | Full Citation | Find Related Articles | | Eriksson BI, Agnelli G, Cohen AT, et al.
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
J Thromb Haemost 2003 Dec; 1(12):2490-6.
Abstract | Full Citation | Find Related Articles | | Eriksson BI, Borris LC, Dahl OE, et al.
Dose-escalation study of rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor - for the prevention of venous thromboembolism in patients undergoing total hip replacement. [JOURNAL ARTICLE]
Thromb Res 2007 Feb 9.
Abstract | Full Citation | | Navarro-Quilis A, Castellet E, Rocha E, et al.
Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
J Thromb Haemost 2003 Mar; 1(3):425-32.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| |
Advertise on this site.
|
